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http://www.biomedcentral.com/1471-2458/13/1106RESEARCH ARTICLE Open AccessEffect of breastfeeding promotion interventions
on cost-effectiveness of rotavirus immunization
in Indonesia
Auliya A Suwantika1,2* and Maarten J Postma1Abstract
Background: Rotavirus infection has been reported to be responsible for the majority of severe diarrhea in children
under-5-years-old in Indonesia. Breast milk is considered to give protection against rotavirus infection. Increasing
breastfeeding promotion programs could be an alternative target to reduce the incidence of rotavirus diarrhea.
This study aims to investigate the effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus
immunization in Indonesia, focusing on breastfeeding education and support interventions.
Methods: An age-structured cohort model was developed for the 2011 Indonesia birth cohort. We compared four
interventions in scenarios: (i) base-case (I0) reflecting the current situation for the population of under-5-years-old,
(ii) with an additional breastfeeding education intervention (I1), (iii) with a support intervention on initiation and
duration (I2) and (iv) with both of these two interventions combined (I3). The model applied a 5-years time horizon,
with 1 month analytical cycles for children less than 1 year of age and annually thereafter. Monte Carlo simulations
were used to examine the economic acceptability and affordability of rotavirus vaccination.
Results: Rotavirus immunization would effectively reduce severe cases of rotavirus during the first 5 years of a
child's life even assuming various breastfeeding promotion interventions. The total yearly vaccine cost would
amount to US$ 64 million under the market vaccine price. Cost-effectiveness would increase to US$ 153 per qual-
ity-adjusted-life-year (societal perspective) with an optimal breastfeeding promotion intervention. Obviously, this is
much lower than the 2011 Gross Domestic Product (GDP) per capita of US$ 3,495. Affordability results showed that
at the market vaccine price, rotavirus vaccination could be affordable for the Indonesian health system.
Conclusions: Rotavirus immunization would be a highly cost-effective public health intervention for Indonesia
even under various breastfeeding promotion interventions based on the WHO’s criteria for cost-effectiveness in
universal immunization.
Keywords: Rotavirus, Cost-effectiveness, Vaccination, Breastfeeding, AffordabilityBackground
Despite the common practice of breastfeeding in develop-
ing countries, exclusive breastfeeding remains uncommon
[1]. There is still a big challenge for healthcare profes-
sionals to encourage women to breastfeed exclusively.
The World Health Organization (WHO) recommends
exclusive breastfeeding for the first 6 months of life and
continuing partially breastfeeding up to 2 years of age* Correspondence: a.a.suwantika@rug.nl
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Pharmacy, University of Groningen, Groningen, The Netherlands
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distribution, and reproduction in any mediumand beyond. Obviously, a focus both on initiating and
continuing breastfeeding is very important to reduce the risk
of failure on breastfeeding start and maintenance [2]. Yet,
practice deviates from these recommendations. In particular,
the low uptake of exclusive breastfeeding might be caused
by the lack of breastfeeding support and education [3].
The WHO estimated that optimized breastfeeding would
save 1.45 million children’s lives each year in developing
countries due to averting diarrhea and respiratory tract
infections [4]. In Indonesia, rotavirus infection has been
reported to be responsible for the majority of severe
diarrhea in children under-5-years-old, mainly in childrened Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sidered to give protection against rotavirus infection
because it contains anti-rotavirus maternal antibodies
and other nonspecific inhibitors [6]. Therefore, increasing
breastfeeding promotion programs in Indonesia could be
an alternative target to reduce the incidence of rotavirus
diarrhea.
In terms of the health economic perspective, a previous
study confirmed that implementation of rotavirus vaccin-
ation in Indonesia could be cost-effective [7]. Notably,
the previous study did not take breastfeeding explicitly
into account and did not consider the effect of potential
breastfeeding promotion interventions on cost-effectiveness
of rotavirus immunization. Considering these limita-
tions of the previous study and the need to explore
the impact of breastfeeding promotion in childhood
vaccination, we investigated the effect of breastfeeding
promotion interventions on cost-effectiveness of rota-
virus immunization in Indonesia, focusing on breast-
feeding education and support intervention. Specifically,
optimized breastfeeding might impact the economic
evaluation results since maternal protection would be
enhanced. Yet, cost-effectiveness could still be accept-
able even in that situation. In this study we applied a
cost-effectiveness model developed by University of
Groningen labeled “Consensus Model on Rotavirus
Vaccination” (CoRoVa), in the context of the Indonesian
healthcare system for the next 5 years [8].
Methods
We applied the CoRoVa model, previously used to esti-
mate cost-effectiveness of rotavirus vaccination both in
developing and developed countries. The model is
extensively validated and has the ability to calculate
potential impact of breastfeeding on vaccination cost-Base-case (I0)
NBF: 12,283,920
PBF:   7,289,285
















Figure 1 Scheme for estimation of RV-diarrhea cases for all interventeffectiveness. Considering 4,200,000 infants [7] reflecting
2011 Indonesia birth cohort and using the data from the
Indonesian Demographic and Health Survey (IDHS) on
the age-specific breastfeeding patterns [9], we constructed
an age-structured model with a 5-years time horizon
based on breastfeeding statuses. In particular, we consid-
ered exclusive, partial or no breastfeeding as categories. In
this study, we compared four scenarios: (i) base-case (I0)
reflecting the current situation for the population of
under-5-years-old, (ii) with an additional breastfeeding
education intervention (I1), (iii) with a support interven-
tion on initiation and duration (I2) and (iv) with both of
these two interventions combined (I3) (see Figure 1). The
5-year time horizon was chosen as rotavirus infection
has been reported to be responsible for the majority of
severe diarrhea cases in population under-5-years-old in
Indonesia, and the severity rapidly decreases over 5 years
[5]. Based on previous studies, each intervention could
be assumed to increase the breastfeeding rate and cor-
respondingly reduce the incidence of rotavirus-diarrhea
[1,3,10-12]. Aligning with the global health outcomes
chosen in the previous study, we used the four severity levels
of rotavirus-diarrhea; i.e. mild (home treatment), moderate
(general practitioner treatment), severe (hospitalization)
and death [13]. We ran the model in Microsoft Excel
2010 and used @ Risk 4.5.4 for probabilistic sensitivity
analysis.
Applying the data from the 2007 IDHS on breastfeed-
ing status by age and considering the WHO’s recom-
mendation on breastfeeding duration, we populated the
under-5-years-old population in Indonesia into the rele-
vant age groups (0–5, 6–11, 12–23, 24–35, 36–47 and
48–59 months) based on breastfeeding statuses: exclu-
sive breastfeeding (EBF), partial breastfeeding (PBF) and
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6-months-old population: 32.4% EBF, 59.1% PBF and 8.5%
NBF [9]. For 6–11, 12–23 and 24–35 months, we applied
the proportions of EBF:PBF:NBF at 3.1%:82.0%:14.9%,
0.3%:31.7%:68.0% and 0.1%:30.1%:69.8%, respectively
[9]. For 36–47 months, the proportions were assumed
to be 0%:10%:90%, and for 48–59 months, we assumed
100% NBF.
Due to lack of data on 2011 diarrhea cases for under-
5-years-old in Indonesia, we estimated 2011 diarrhea cases
over breastfeeding statuses by applying 2007 data on diar-
rhea cases and considering the WHO’s data on relative
risk of diarrhea morbidity by feeding statuses [15]. Add-
itionally, we made an assumption that the same number
of diarrhea cases as estimated for 2007 would overall apply
to 2011 in Indonesia as well. Based on a 2009 study on
economic evaluation of a routine rotavirus vaccination
in Indonesia [7], we divided rotavirus-diarrhea cases
into respective levels of severity by using proportions of
76.0%, 22.9% and 1.16% for outpatient visits (moderate
and mild cases), hospitalization (severe cases) and fatal
cases. Additionally, we estimated that moderate cases
would be 38.7% from mild cases [16]. These numbers
would subsequently reflect diarrhea cases in the base-
case (I0) in our study.
Assuming I0 as condition without breastfeeding pro-
motion interventions in Indonesia, we compared it with
three intervention scenarios as mentioned. Firstly, we
assumed a breastfeeding education intervention (I1).
Based on the WHO’s 2009 study in Iran [10], we assumed
the same method and considered the same effect on
increasing the rate of EBF. This method was initiated
when a mother stayed for 24-hours in a postpartum
ward [10]. It required a 40-hours training in total dur-
ing several days by on the advantages of breastfeeding
and the importance of EBF [10]. On the initial day of
discharge, the mother and her baby were observed on
taking the right breastfeeding position with follow-up
visits at days 10, 15 and 30 after delivery [10]. Consid-
ering the odds ratio (OR) on feeding patterns after
4 months delivery in the study and control groups be-
tween EBF (OR = 16.89; 95%CI = 5.42-52.59; p < 0.0001),
PBF (OR = 0.22; 95%CI = 0.10-0.49; p = 0.0002) and NBF
(OR = 0.24; 95%CI = 0.06-0.92; p = 0.04) [10], we estimated
the EBF-rate could be 120% higher compared to cases
without an intervention on a 5-years time horizon. We
assumed that the increasing rate of EBF reduces propor-
tions of PBF and NBF at the same rates in each age
group; i.e. the relative sizes of PBF and NBF remain
the same as in I0. We estimated the program could re-
duce rotavirus-diarrhea cases for under-5-years-old by
2% [10,11,17].
Secondly, we analyzed breastfeeding support interven-
tion (I2). This method has been applied among a group oflow income women in the US, where they were trained
and motivated on initiating and continuing to breastfeed
and had to meet a lactation consultant individually to dis-
cuss breastfeeding during pregnancy [3]. This method was
followed-up at 4 days, 2-3-4-6 weeks, 3-4-5-6 months
postpartum to ascertain on managing and continuing to
breastfeed [3]. Applying the OR proportion of women
breastfeeding after 6 months intervention [3] and consid-
ering the mean difference for education (I1) and support
(I2) with three outcome measures (initiation, short-term
and long-term duration) [18], we estimated the program
could increase the proportion of EBF up to 84% higher as
compared to no program and could reduce rotavirus-
diarrhea cases for under-5-years-old by 1.4% [3,11,15,18].
Thirdly, we assumed a combined effect of education
and support interventions (I3) [18]. We considered to apply
the best effect between education, support and reported
combined effects for initiation (mean difference = 23%;
95%CI = 12%-34%), short-term (mean difference = 23%;
95%CI = 12%-34%) and long-term duration (mean dif-
ference = 23%; 95%CI = 12%-34%), respectively [18]. We
calculated that the combined effect could increase the
probability of EBF up to 179% higher as compared to no
program and could reduce rotavirus-diarrhea cases for
under-5-years-old by 3% [3,11,15,18]. For all interven-
tion scenarios (I1, I2 and I3), we assumed the proportion
of rotavirus-diarrhea cases in each age group to remain
the same as in I0.
We assumed that the RotaTeq vaccine in three doses
is used in our study. For formula-fed infants (NBF), we
applied the rotavirus vaccine efficacies at 70%, 84% and
76.5% as initial vaccine effectiveness for mild-moderate,
severe and fatal cases, respectively [7]. We calculated the
vaccine efficacies for breastfed infants (EBF and PBF) at
63.1%, 75.7% and 68.9% for mild-moderate, severe and
fatal cases, respectively, by considering the results from
a study by Vesikari et al. on rotavirus vaccine efficacy in
breast-fed European infants, and a comparative study on
rotavirus vaccine efficacy in low, middle and high socio-
economic settings by Lopman et al. [6,19]. Based on a
previous study, we assumed that the vaccine effectiveness
would exponentially decreased by 11% per year [20]. For
between-dose efficacy, we applied 82% (between doses 1
and 2) and 84% (between doses 2 and 3) of full effective-
ness [20,21]. We applied 2011 DPT vaccine coverage at
94% [22] as rotavirus vaccine coverage. We obtained the
quality-adjusted-life-year (QALY) losses data by consider-
ing the disutility of each severity level and its duration
from earlier works [16]. However, in this study we did not
consider QALY-losses in caregivers.
In terms of economic perspectives, we analyzed the
data both from the healthcare and societal perspectives.
From the healthcare perspective, we only considered dir-
ect medical costs while from the societal perspective we
Table 1 Parameters used in the economic model
Parameters Base-case value Distribution References
Vaccine coverage 94% Triangular (89%; 94%; 99%) [22]
Vaccine efficacy in formula-fed infants
Mild 70.0% Triangular (66.5%; 70.0%; 73.5%) [7]
Moderate 70.0% Triangular (66.5%; 70.0%; 73.5%)
Severe 84.0% Triangular (79.8%; 84.0%; 88.2%)
Death 76.5% Triangular (72.7%; 76.5%; 80.3%)
Vaccine efficacy in breast-fed infants
Mild 63.1% Triangular (59.9%; 63.1%; 66.2%) [6,7,9]; calculated
Moderate 63.1% Triangular (59.9%; 63.1%; 66.2%)
Severe 75.7% Triangular (71.9%; 75.7%; 79.5%)
Death 68.9% Triangular (65.5%; 68.9%; 72.4%)
Rotavirus-diarrhea cases
Base-case
EBF 15,626 Normalised mean: 15,626 (90%CI; 15,382-15,871) [7,9,14-16,20]; calculated
PBF 452,658 Normalised mean: 452,658 (90%CI; 451,412-453,903)
NBF 450,261 Normalised mean: 450,261 (90%CI; 449,018-451,504)
Education
EBF 36,674 Normalised mean: 36,674 (90%CI; 36,300-37,047) [7,9,10,14-16,20]; calculated
PBF 420,264 Normalised mean: 420,264 (90%CI; 419,058-421,469)
NBF 442,056 Normalised mean: 442,056 (90%CI; 440,824-443,289)
Support
EBF 38,321 Normalised mean: 38,321 (90%CI; 37,940-38,703) [3,7,9,14-16,18,20]; calculated
PBF 422,586 Normalised mean: 422,586 (90%CI; 421,378-423,795)
NBF 441,548 Normalised mean: 441,548 (90%CI; 440,316-442,780)
Combined Effects [7,9,14-16,18,20]; calculated
EBF 57,824 Normalised mean: 57,824 (90%CI; 57,356-58,292)
PBF 394,543 Normalised mean: 394,543 (90%CI; 393,371-395,715)
NBF 433,441 Normalised mean: 433,441 (90%CI; 432,220-434,663)
Utility losses




Total medical direct costs per case
(healthcare perspective, US$)
Mild 1.08 Triangular (1.08; 1.44; 1.80) [23]
Moderate 4.31 Triangular (3.23; 4.31; 5.39) [7]
Severe 41.72 Triangular (31.29; 41.72; 52.15) [7]
Total direct and indirect costs per case
(societal perspective, US$)
Mild 2.81 Triangular (2.11; 2.81; 3.52) [23]
Moderate 5.69 Triangular (4.27; 5.69; 7.11) [7]
Severe 56.34 Triangular (42.25; 56.34; 70.42) [7]
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Table 1 Parameters used in the economic model (Continued)
Total vaccination and administration cost
(per child, US$)
3-dose, Market price 15.50 Alternative scenario [7,20]
Discount rate 3% Unvaried [14,20]
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non-medical and indirect cost) [7]. We calculated all
costs due to rotavirus-diarrhea for severe and moderate
cases by considering 2007 data on hospitalization and
outpatient visit costs due to rotavirus-diarrhea in Indonesia
[7]. For mild cases, we estimated direct medical cost
from the expenditure per child of oral-rehydration-therapy
(ORT) in diarrhea treatment for children under-5-years-old
[23]. We converted these costs into 2011 US$ by consider-
ing the annual inflation rates.
Finally, we compared the reduction in rotavirus cases,
QALY losses, and the cost-of-illness due to rotavirus-
diarrhea. Using a market price of US$ 5 per dose [20], we
estimated the incremental cost-effectiveness ratio (ICER)
per QALY for all four scenarios. Applying the WHO’s
definition on cost-effectiveness of universal immunization
according to the GDP-per-capita, (i) highly cost-effective
(less than one GDP-per-capita); (ii) cost-effective (between
1 and 3 times GDP-per-capita); and (iii) cost-ineffective
(more than 3 times GDP-per-capita) [24], we specifically
evaluated the results of rotavirus vaccination in Indonesia
in all four scenarios.
We performed univariate and probabilistic sensitivity
analyses. We investigated the effects of different input
parameters by varying each parameter at value of ± 25%
while keeping other parameters constant in univariate
sensitivity analyses. In the context of breastfeeding pro-
motion interventions in this study, we varied from the
minimal intervention (I2) to the maximal intervention
(I3). Furthermore, probabilistic sensitivity analysis (PSA)
was performed by running 5000 Monte Carlo simula-
tions. We evaluated the affordability related to the required
budget for vaccination (vaccination costs + treatment costs)
to analyze the budget impacts on the implementation of
vaccination from the healthcare perspective, which is
relevant for assisting decision makers in the health sec-
tor. All input parameters are shown in Table 1.
Results
Assuming 94% vaccine coverage [22], vaccination of
4,200,000 birth cohort [7] would reduce rotavirus-
diarrhea with 513,796 cases in I0. Considering breast-
feeding promotion interventions, vaccination would
reduce rotavirus-diarrhea by 506,694; 508,601 and 502,793
for I1, I2 and I3, respectively (see Table 2). From the soci-
etal perspective, vaccination would save US$ 8,369,236
in cost-of-illness due to rotavirus-diarrhea in I0 andwith breastfeeding promotion interventions it would
save US$ 8,245,065; US$ 8,277,719 and US$ 8,177,772
for I1, I2 and I3, respectively. For QALYs loss, vaccination
would save 348,887 discounted QALYs in I0 and with
breastfeeding promotion interventions it would save
343,534; 344,926 and 340,653 for I1, I2 and I3, respectively.
With a market price of US$ 5 per dose [20], cost-
effectiveness values from the societal perspective are US$
149, US$ 152, US$ 151 and US$ 153 for I0, I1, I2 and I3,
respectively (see Figure 2). The results are far below
the 2011 Indonesian GDP-per-capita of US$ 3,495
[25]. Obviously, according to the WHO’s definition for
cost-effectiveness [24], rotavirus immunization is a
highly cost-effective intervention even assuming vari-
ous breastfeeding promotion interventions. Notably,
with an optimal breastfeeding promotion intervention
(I3), cost-effectiveness would increase to US$ 153
(societal perspective), although the cost-effectiveness
is still far below the WHO threshold.
The impacts of parameter changes on the ICERs are
shown in a tornado chart (see Figure 3). The results con-
firmed that the mortality rate and vaccine price were the
most influential parameters in the sensitivity analyses.
The cost-effectiveness results were not sensitive to the mild
cost, moderate cost, severe cost, mild incidence, moderate
incidence, severe incidence, breastfeeding promotions
and vaccine efficacies.
At a threshold ICER of US$ 149 (the base case value
from the societal perspective), the probability for the
vaccination program to be cost-effective would be 59%;
9%; 19% and 2% for I0, I1, I2 and I3, respectively. Already
at a threshold ICER of US$ 158, the probability for the
vaccination program to be cost-effective would be 100%
for all scenarios (see Figure 4a). From the healthcare
perspective, rotavirus immunization with a market price
of US$ 5 per dose would always be implementable when
the budget exceeds US$ 64,080,000; US$ 63,960,000;
US$ 63,995,000 and US$ 63,905,000 for I0, I1, I2 and I3,
respectively (see Figure 4b).
Discussion
Compared to the base case (I0), breastfeeding interven-
tions would increase EBF-rate by 120%, 84% and 179%
for I1, I2 and I3, respectively, as mentioned. At the market
vaccine price of US$ 5 per dose, a rotavirus immunization
program in Indonesia could reduce rotavirus-diarrhea by
259,390; 118,520; 129,886 and 6,000 for mild, moderate,
Table 2 Results for all interventions
No Vaccination Vaccination j Difference
Base-case (I0)
a
Number of RV-diarrhea cases e,f 918,545 404,749 513,796
Mild cases 503,190 243,800 259,390
Moderate cases 194,734 76,214 118,520
Severe cases 209,970 80,084 129,886
Death cases 10,651 4,651 6,000
QALYs lost g 616,904 268,027 348,887
Cost of illness (healthcare perspective) g,h $ 9,887,025 $ 3,839,484 $ 6,047,541
Cost of illness (societal perspective) g,i $ 13,748,048 $ 5,378,812 $ 8,369,236
Education (I1)
b
Number of RV-diarrhea cases e,f 900,307 393,613 506,694
Mild cases 493,198 237,539 255,659
Moderate cases 190,868 73,765 117,103
Severe cases 205,801 77,784 128,017
Death cases 10,440 4,525 5,915
QALYs lost g 603,799 260,265 343,534
Cost of illness (healthcare perspective) g,h $ 9,681,360 $ 3,723,490 $ 5,957,870
Cost of illness (societal perspective) g,i $ 13,462,069 $ 5,217,004 $ 8,245,065
Support (I2)
c
Number of RV-diarrhea cases e,f 905,354 396,753 508,601
Mild cases 495,963 239,315 256,648
Moderate cases 191,938 74,435 117,503
Severe cases 206,955 78,442 128,513
Death cases 10,498 4,561 5,937
QALYs lost g 607,368 262,442 344,926
Cost of illness (healthcare perspective) g,h $ 9,737,646 $ 3,756,191 $ 5,981,455
Cost of illness (societal perspective) g,i $ 13,540,335 $ 5,262,616 $ 8,277,719
Combined Effects (I3)
d
Number of RV-diarrhea cases e,f 890,455 387,662 502,793
Mild cases 487,802 234,175 253,627
Moderate cases 188,779 72,480 116,309
Severe cases 203,549 76,549 127,000
Death cases 10,325 4,458 5,867
QALYs lost g 596,795 256,142 340,653
Cost of illness (healthcare perspective) g,h $ 9,571,093 $ 3,661,825 $ 5,909,268
Cost of illness (societal perspective) g,i $ 13,308,742 $ 5,130,971 $ 8,177,772
a Actual distribution over the different BF patterns.
b Population <2 years old with 100% EBF.
c Population <2 years old with 100% PBF.
d Population <2 years old with 100% NBF.
e Population <5 years old.
f Undiscounted.
g Discounted.
h Direct medical cost.
i Direct medical + direct non-medical + indirect cost.
j Costs are excluding vaccination cost.


















Figure 2 Cost-effectiveness value for all interventions.
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http://www.biomedcentral.com/1471-2458/13/1106severe and fatal cases, respectively. Assuming the base-
case (I0) as a condition without breastfeeding promotion
interventions in Indonesia, breastfeeding promotion in-
terventions could reduce rotavirus-diarrhea from I0 by
1.4% - 3.1% for I1, I2 and I3. From the social perspective,
the incremental cost-effectiveness ratios are US$ 149;
US$ 152; US$ 151 and US$ 153 for I0, I1, I2 and I3,
respectively. Notably, our assumption that breastfeeding
might decrease the effectiveness of rotavirus immunization
is congruent with other studies [4,6,26]. Furthermore, based
on the WHO’s criteria for cost-effectiveness in universal
vaccination, our results confirm that rotavirus vaccination
would be a highly cost-effective public health intervention
for Indonesia even under various breastfeeding promotion
interventions [24].
In our study we took uncertainties into account by
using univariate and probabilistic sensitivity analyses.
The sensitivity analyses showed that the mortality rate
and vaccine price were the most influential parametersvaccine efficacy in breast-fed infants (mild-moderat
vaccine efficacy in breast-fed infants (sever
vaccine efficacy in breast-fed infants (deat
vaccine efficacy in formula-fed infants (mild-moderat
vaccine efficacy in formula-fed infants (sever










Figure 3 Results of univariate sensitivity analyses.impacting the cost-effectiveness results. The results on
this study reconfirmed the results from previous studies
on cost-effectiveness of rotavirus immunization [16,27].
Postma et al. also found that the cost-effectiveness of
rotavirus immunization in South East Asia Region (SEAR)
was highly sensitive to the mortality rate and vaccine price
[16]. A critical review on cost-effectiveness of rotavirus
vaccination previously also mentioned mortality as the
most influential parameter for middle and low income
countries [27].
We found a similar required funds (vaccination and
treatment costs) for childhood vaccination. Considering
the market vaccine price of US$ 5 per dose, rotavirus
vaccination would require a budget of US$ 63,905,000 –
US$ 64,080,000. Despite all interventions required the
same budget for the vaccination costs, the results indi-
cated that breastfeeding promotion could provide some
potentials to decrease the treatment costs for rotavirus
immunization in Indonesia due to its effect on reducing
rotavirus-diarrhea cases. Thus, breastfeeding promotion
interventions could potentially result in less opportun-
ities for cost offsets of vaccination. Compared to the
total Indonesian government health budget for the whole
immunization program in 2011 (US$ 198 million) [28],
the required fund by the government for universal rota-
virus vaccination would yet be unrealistic. Next to po-
tentially manufacturing a rotavirus vaccine nationally at
much lower costs prices, support could be considered
to achieve subsidized affordable prices.
Our study is not the first study on the economic ana-
lysis of rotavirus vaccination in Indonesia but it could
provide crucial information for the policy makers spe-
cifically on the potential introduction of breastfeedingICER









































































Figure 4 Cost-effectiveness acceptability and affordability curves. (a) Cost-effectiveness acceptability curves from the societal perspective.
(b) Affordability curves from the healthcare perspective.
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immunization in National Immunization Programmes
(NIP). This combined approach would increase the EBF-
rate and reduce rotavirus-diarrhea cases at potential cost-
effective efforts. We extended the CoRoVa model that has
been used in a previous study to calculate cost-effectiveness
of rotavirus for both developed and developing countries,
by taking breastfeeding into account and investigating
explicitly the effect of breastfeeding promotion interven-
tions on cost-effectiveness of rotavirus immunization in
Indonesia. The relationships between breastfeeding prac-
tice, breastfeeding promotion and rotavirus-diarrhea are
well-known and therefore important to be included in our
modeling approach. Despite that several other interven-
tions on breastfeeding promotion were mentioned in pre-
vious study [29], in this study we limited ourselves to two
mostly-used interventions of breastfeeding education and
support intervention.
We noted several limitations in our study. Firstly, due
to lack of data on herd immunity, we had to apply a
static model instead of a dynamic model. If we were to
include herd immunity in a dynamic analysis there wouldbe greater impacts of rotavirus vaccination and its cost-
effectiveness would be further improved. Secondly, we
noted lack of 2011 data on rotavirus-diarrhea incidence
in Indonesia and actual data on implementation of breast-
feeding promotion interventions. We applied 2007 data
on rotavirus-diarrhea incidence from a previous study
and assumed it would be the same with 2011, while for
the implementation of breastfeeding promotion inter-
ventions, we assumed that the base-case is a condition
without specific breastfeeding promotion interventions
in recent years. To overcome this limitation, we varied
these assumptions extensively in multiple sensitivity ana-
lysis. Finally, we only obtained treatment costs for 2007 and
we adjusted to 2011 values by considering the inflation rate.
Due to the low uptake of EBF in Indonesia and the high
prevalence of rotavirus-diarrhea in population under-5-
years-old, policy makers in Indonesia should consider
taking action to enhance the introduction of rotavirus
vaccination and designing more intensive programs on
breastfeeding promotion interventions. We showed that
this approach is potentially highly cost-effective. How-
ever, as a developing country, Indonesia is faced with
Suwantika and Postma BMC Public Health 2013, 13:1106 Page 9 of 9
http://www.biomedcentral.com/1471-2458/13/1106limited resources especially on providing required budget
both for implementation of rotavirus vaccination and breast-
feeding promotion interventions. Getting funds from
international organizations could be realistic sollution
to overcome this problem. Hopefully, this assists the
Indonesian government in designing optimal policies
both in increasing the EBF-rate and in reducing the
incidence of rotavirus-diarrhea.
Conclusion
Rotavirus immunization is a highly cost-effective inter-
vention for the Indonesian healthcare system even under
various breastfeeding promotion interventions based on
the WHO’s criteria for cost-effectiveness in universal
immunization. Yet, the implementation of rotavirus
immunization in Indonesia would be unrealistic without
international organization support.
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